NASDAQ: CERS | Healthcare / Biotechnology / USA |
6.24 | +0.1700 | +2.80% | Vol 823.62K | 1Y Perf 19.88% |
Apr 13th, 2021 14:30 DELAYED |
BID | 6.24 | ASK | 6.25 | ||
Open | 6.08 | Previous Close | 6.07 | ||
Pre-Market | 6.09 | After-Market | - | ||
0.02 0.33% | - - |
Target Price | 9.10 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 47.25 | Finscreener Ranking | ★★★ 50.58 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★+ 45.41 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★ 47.74 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Market Cap | 1.05B | Earnings Rating | Buy | |
Price Range Ratio 52W % | 34.25 | Earnings Date | 4th May 2021 |
Today's Price Range 6.056.25 | 52W Range 4.878.87 | 5 Year PE Ratio Range -8.40-7.60 |
Summary:
Neutral
Technical Indicators: | Buy |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -0.16% | ||
1 Month | -5.01% | ||
3 Months | -18.41% | ||
6 Months | -9.67% | ||
1 Year | 19.88% | ||
3 Years | 12.83% | ||
5 Years | -2.41% | ||
10 Years | 125.65% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -91.59 | |||
ROE last 12 Months | -72.15 | |||
ROA (5Y Avg) | -33.19 | |||
ROA last 12 Months | -29.81 | |||
ROC (5Y Avg) | -60.32 | |||
ROC last 12 Months | -40.03 | |||
Return on invested Capital Q | -7.97 | |||
Return on invested Capital Y | -39.10 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 4.40 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-16.90 | ||||
9.84 | ||||
11.51 | ||||
- | ||||
-46.20 | ||||
-0.25 | ||||
9.96 | ||||
0.62 | ||||
954.39M | ||||
Forward PE | -19.15 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
2.60 | ||||
3.10 | ||||
0.35 | ||||
0.64 | ||||
-14.90 | ||||
Leverage Ratio | 2.00 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
55.20 | ||||
-48.90 | ||||
-46.10 | ||||
-94.70 | ||||
-47.86 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
89.61M | ||||
0.53 | ||||
23.94 | ||||
29.47 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2020 | -0.08 | -0.09 | -12.50 |
Q03 2020 | -0.12 | -0.08 | 33.33 |
Q02 2020 | -0.10 | -0.09 | 10.00 |
Q01 2020 | -0.10 | -0.10 | 0.00 |
Q04 2019 | -0.11 | -0.12 | -9.09 |
Q03 2019 | -0.11 | -0.13 | -18.18 |
Q02 2019 | -0.12 | -0.13 | -8.33 |
Q01 2019 | -0.12 | -0.14 | -16.67 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
3/2021 QR | -0.09 | 70.00 | Positive |
6/2021 QR | -0.08 | 73.33 | Positive |
12/2021 FY | -0.33 | - | - |
12/2022 FY | -0.32 | - | - |
Next Report Date | 4th May 2021 |
Estimated EPS Next Report | -0.09 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 823.62K |
Shares Outstanding | 168.22M |
Trades Count | 6.00K |
Dollar Volume | 24.89M |
Avg. Volume | 2.22M |
Avg. Weekly Volume | 1.28M |
Avg. Monthly Volume | 2.19M |
Avg. Quarterly Volume | 2.26M |
Cerus Corporation (NASDAQ: CERS) stock closed at 6.07 per share at the end of the most recent trading day (a -0.98% change compared to the prior day closing price) with a volume of 916.57K shares and market capitalization of 1.05B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 270 people. Cerus Corporation CEO is William M. Greenman.
The one-year performance of Cerus Corporation stock is 19.88%, while year-to-date (YTD) performance is -12.28%. CERS stock has a five-year performance of -2.41%. Its 52-week range is between 4.87 and 8.87, which gives CERS stock a 52-week price range ratio of 34.25%
Cerus Corporation currently has a PE ratio of -16.90, a price-to-book (PB) ratio of 9.84, a price-to-sale (PS) ratio of 11.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -29.81%, a ROC of -40.03% and a ROE of -72.15%. The company’s profit margin is -47.86%, its EBITDA margin is -46.10%, and its revenue ttm is $89.61 Million , which makes it $0.53 revenue per share.
Of the last four earnings reports from Cerus Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Cerus Corporation’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for Cerus Corporation is Strong Buy (1), with a target price of $9.1, which is +47.25% compared to the current price. The earnings rating for Cerus Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cerus Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cerus Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.75, ATR14 : 0.55, CCI20 : -0.46, Chaikin Money Flow : 0.08, MACD : -0.33, Money Flow Index : 46.90, ROC : 4.12, RSI : 41.64, STOCH (14,3) : 61.62, STOCH RSI : 0.93, UO : 44.77, Williams %R : -38.38), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cerus Corporation in the last 12-months were: Carol M. Moore (Option Excercise at a value of $450 457), Carol M. Moore (Sold 181 646 shares of value $1 253 915 ), Chrystal Menard (Option Excercise at a value of $1 141 904), Chrystal Menard (Sold 304 787 shares of value $2 368 738 ), Daniel N. Swisher (Option Excercise at a value of $58 000), Daniel N. Swisher (Sold 20 000 shares of value $140 302 ), Eric H. Bjerkholt (Option Excercise at a value of $0), Gail Gaumer Schulze (Option Excercise at a value of $37 200), Gail Gaumer Schulze (Sold 62 393 shares of value $456 817 ), Jami Dover Nachtsheim (Option Excercise at a value of $0), Kevin D. Green (Option Excercise at a value of $166 400), Kevin D. Green (Sold 101 513 shares of value $658 540 ), Laurence M. Corash (Option Excercise at a value of $346 968), Richard J. Benjamin (Option Excercise at a value of $1 180 028), Richard J. Benjamin (Sold 254 583 shares of value $1 903 044 ), Timothy B. Anderson (Option Excercise at a value of $655 958), Timothy B. Anderson (Sold 135 496 shares of value $1 023 622 ), Timothy L. Moore (Option Excercise at a value of $0), Vivek K. Jayaraman (Option Excercise at a value of $406 031), Vivek K. Jayaraman (Sold 143 895 shares of value $1 151 160 ), William M. Greenman (Option Excercise at a value of $300 000), Witney Frank (Option Excercise at a value of $0)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: blood safety and generates revenue from the same.
CEO: William M. Greenman
Telephone: +1 925 288-6000
Address: 1220 Concord Avenue, Concord 94520, CA, US
Number of employees: 270
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE BZX (BATS) real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2021. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.